Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Trial Profile

Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Everolimus; Sirolimus
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top